Tango Therapeutics went public via a SPAC merger with BCTG Acquisition in a $353m.

Tango Therapeutics, a biotechnology company, went public via a SPAC merger with BCTG Acquisition in a $353m. Investors in the PIPE include lead investor and SPAC sponsor Boxer Capital, as well as Avoro Capital, Bain Capital Life Sciences, funds and accounts managed by Blackrock, EcoR1 Capital, Farallon Capital, Fidelity Management & Research Company, Foresite Capital, Janus Henderson Investors, Logos Capital, RA Capital Management, Samsara BioCapital, Southpoint Capital, Surveyor Capital and Woodline Partners LP, in addition to existing Tango Therapeutics shareholders including Casdin Capital, Cormorant Asset Management and Gilead Sciences. “Our strategy for developing precision oncology therapies, along with the capital raised from this transaction, positions us well to advance our lead programs into the clinic, developing potentially transformational therapies for genetically-defined patient populations. I want to again thank the many people involved in making this transaction a success, including our new and existing investors, and the Tango, Boxer and BCTG teams,” Barbara Weber, Managing Director, President and CEO.